| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Cholesterol Lowering Guidelines: From Whence We Came and Where We Are Now
|
Waters, David D.
|
|
2019
|
35 |
5 |
p. 590-597
|
artikel
|
| 2 |
Dietary Sodium and the Health of Canadians
|
Campbell, Norm R.C.
|
|
2019
|
35 |
5 |
p. 671.e1
|
artikel
|
| 3 |
Editorial Board
|
|
|
2019
|
35 |
5 |
p. A3-A4
|
artikel
|
| 4 |
Evolution of Blood Pressure Clinical Practice Guidelines: A Personal Perspective
|
Whelton, Paul K.
|
|
2019
|
35 |
5 |
p. 570-581
|
artikel
|
| 5 |
Functional Dosage of Muscarinic Cholinergic Receptor 3 Signalling, Not the Gene Dose, Determines Its Hypertension Pathogenesis
|
Deng, Alan Y.
|
|
2019
|
35 |
5 |
p. 661-670
|
artikel
|
| 6 |
Guideline Alignment in Related Areas
|
Dubrofsky, Lisa
|
|
2019
|
35 |
5 |
p. 606-610
|
artikel
|
| 7 |
Guideline Implications of Prothrombotic State Assessment in Low-Risk Atrial Fibrillation Patients: Consistency With CHA2DS2-VASc and Support for CHADS-65
|
Nattel, Stanley
|
|
2019
|
35 |
5 |
p. 547-549
|
artikel
|
| 8 |
Hypertension Guidelines: Effect of Blood Pressure Targets
|
Touyz, Rhian M.
|
|
2019
|
35 |
5 |
p. 564-569
|
artikel
|
| 9 |
Importance of Risk Reassessment in Patients With Atrial Fibrillation in Guidelines: Assessing Risk as a Dynamic Process
|
Chang, Ting-Yung
|
|
2019
|
35 |
5 |
p. 611-618
|
artikel
|
| 10 |
Information for Readers
|
|
|
2019
|
35 |
5 |
p. A10
|
artikel
|
| 11 |
Muscarinic Receptor Type-3 in Hypertension and Cholinergic-Adrenergic Crosstalk: Genetic Insights and Potential for New Antihypertensive Targets
|
Alves-Lopes, Rhéure
|
|
2019
|
35 |
5 |
p. 555-557
|
artikel
|
| 12 |
Prothrombotic State in Atrial Fibrillation Patients With One Additional Risk Factor of the CHA2DS2-VASc Score (Beyond Sex)
|
Głowicki, Błażej
|
|
2019
|
35 |
5 |
p. 634-643
|
artikel
|
| 13 |
Sex-Specific Considerations in Guidelines Generation and Application
|
Tannenbaum, Cara
|
|
2019
|
35 |
5 |
p. 598-605
|
artikel
|
| 14 |
Statin Use in Primary Prevention: A Simple Trial-Based Approach Compared With Guideline-Recommended Risk Algorithms for Selection of Eligible Patients
|
Khunti, Kamlesh
|
|
2019
|
35 |
5 |
p. 644-652
|
artikel
|
| 15 |
Stroke Prevention, Evaluation of Bleeding Risk, and Anticoagulant Treatment Management in Atrial Fibrillation Contemporary International Guidelines
|
Proietti, Marco
|
|
2019
|
35 |
5 |
p. 619-633
|
artikel
|
| 16 |
Table of Contents
|
|
|
2019
|
35 |
5 |
p. A7-A9
|
artikel
|
| 17 |
Temporal Trends of Women Enrollment in Major Cardiovascular Randomized Clinical Trials
|
Gong, Inna Y.
|
|
2019
|
35 |
5 |
p. 653-660
|
artikel
|
| 18 |
The 2018 ACC/AHA Lipid Guidelines: A Little More or Less Canadian?
|
Thanassoulis, George
|
|
2019
|
35 |
5 |
p. 558-563
|
artikel
|
| 19 |
The History of Hypertension Guidelines in Canada
|
Daskalopoulou, Stella S.
|
|
2019
|
35 |
5 |
p. 582-589
|
artikel
|
| 20 |
To Risk Stratify or Not for Statin Therapy
|
Fitchett, David
|
|
2019
|
35 |
5 |
p. 550-551
|
artikel
|
| 21 |
Women in Cardiovascular Clinical Trials—What Are the Barriers to Address to Improve Enrollment?
|
Pacheco, Christine
|
|
2019
|
35 |
5 |
p. 552-554
|
artikel
|
Tijdschrift beschrijving